Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder

Blixeprodil, a novel, oral NMDA receptor antagonist, demonstrated rapid, robust, and durable antidepressant effects in Major Depressive Disorder Rapid and robust antidepressant efficacy demonstrated by a 6.3-point greater reduction in MADRS vs. placebo 24 hours after a single oral dose of...